“What lupus patients fear most is not the pain itself, but being forgotten by the world.”

Today marks the 22nd global “World Lupus Day”. In 2004, the International Lupus Foundation designated May 10 as World Lupus Day, casting a ray of light upon a disease long shrouded in stigma.

A well-known adage in the medical community goes: Lupus can do everything.

If the human body is likened to a fortress, then Systemic Lupus Erythematosus (SLE) is the “mutiny” of the defending army—immune cells mistake healthy tissues for foreign invaders, turning every inch of terrain, from skin and joints to kidneys and the brain, into a potential battlefield.

SLE is a prototypical diffuse connective tissue disease characterized by autoimmune inflammation, with complex pathogenesis and diverse clinical manifestations. Common symptoms include butterfly-shaped erythema, skin rashes, photosensitivity, joint pain and swelling, and organ (e.g., kidney) damage. The exact mechanisms underlying SLE are not yet fully elucidated, but it is currently known to involve genetic, hormonal, and environmental factors (such as viral/bacterial infections and ultraviolet exposure).

As an innovative biotech company deeply rooted in the autoimmune disease space, META is anchored by groundbreaking scientific exploration and committed to pioneering new therapeutic paradigms through fundamental mechanism innovation.

The pathogenesis of systemic autoimmune diseases is complex and multifaceted, with both innate genetics and acquired environmental factors influencing disease onset and progression. Over the past decade, no breakthrough agents or therapies have emerged for the treatment of autoimmune diseases. META’s core R&D pipeline, META-001-AID, focuses on a novel target and mechanism of action in cellular immuno-metabolic regulation—an innovative therapeutic strategy precisely targeting the core pathological pathways of complex diseases such as SLE and multiple sclerosis (MS)—and is now transitioning from laboratory theory to globally promising treatment regimens.

As immunologist Goodnow once said: “We cannot win the genetic lottery, but we can forge the shield of science.”

Within META’s R&D framework, every scientific validation based on novel mechanisms points toward a future worth anticipating—by progressively deciphering the regulatory code of cellular immunometabolism, the clinical outcomes of diseases like SLE are poised to be fundamentally transformed, ensuring that the imprint of disease is no longer a life sentence, but rather a footnote in the annals of medical progress.